Drug trials that have influenced our practice in the treatment of venous thromboembolism

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 553-557

  Kearon, Clive ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; UROKINASE; WARFARIN;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0030813945     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657587     Document Type: Conference Paper

References (61)

1. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19:79-86.
2. Wright IS. Experience with anticoagulants. Circulation 1959; 19: 110-3.
3. Jorpes JE. Heparin: A mucopolysaccharide and an active antithrombotic drug. Circulation 1959; 19:87-91.
4. Mueller RL, Scheidt S. History of drugs for thrombotic disease Discovery, development, and directions for the future. Circulation 1994; 89:432-49.
5. Kakkar VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975; 2:45-51.
6. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1:1309-12.
7. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855-8.
8. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 515-8.
9. Brandjes DPM, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485-9.
10. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969; 2:230-2.
11. Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop Related Res 1991; 273:125-30.
12. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995; 155:366-72.
13. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 1959; 2:981-9.
14. Gallus AS, Hirsh J, Tuttle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288:545-51.
15. Leyvraz PF, Richard J, Bachmann F. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983; 309:954-8.
16. Wille-Jorgensen P, Thorup J, Fischer A, Holst-Christensen J, Flamsholt R. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomized trial. Br J Surg 1985; 72:579-81.
17. Torngren S. Low dose heparin and compression stockings in the prevention of postoperative deep venous thrombosis. Br J Surg 1980; 67:482-4.
18. Ramos R, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109:82-5.
19. Hirsh J, Levine MN. Review: Low molecular weight heparin. Blood 1992; 79(1):1-17.
20. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340:152-6.
21. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305:913-20.
22. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery. Arch Intern Med 1993; 153:2221-8.
23. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271(22):1780-5.
24. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119:1105-12.
25. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335:701-7.
26. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90:2385-9.
27. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347:635-9.
28. Gårdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996; 347:1357-61.
29. Urokinase Pulmonary Embolism Trial. Urokinase pulmonary embolism trial: phase I results. JAMA 1970; 214:2163-72.
30. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49(2):171-84.
31. Basu D, Gallus AS, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287(7):324-7.
32. Salzman EW, Deykin D, Mayer Shapiro R, Rosenberg R. Management of heparin therapy controlled prospective trial. N Engl J Med 1975, 292:1046-50.
33. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993; 119:874-81.
34. Cruickshank MK, Levine MN, Hirsh J, Roberts RS, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333-7.
35. Gallus AS, Jackaman J, Tillett J, Mills W, Sycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2:1293-6.
36. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260-4.
37. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 18(315):1109-14.
38. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307:1676-81.
39. Hirsh J, Poller L. The international normalized ratio: A guide to understanding and correcting its problems. Arch Intern Med 1994; 154:282-8.
40. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothromin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992; 152:278-82.
41. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
42. O'Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972; 2:1104-7.
43. Holmgren KAJ, Andersson G, Fagrell B, et al. One-month versis six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218:279-84.
44. Fennerty AG, Dolben J, Thomas P, et al. A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism. Clin Lab Haematol 1987; 9:17-21.
45. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340:873-6.
46. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Hemost 1995; 74:606-11.
47. Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332:1661-5.
48. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-8.
49. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: meta-analysis. Br Med J 1994; 309:299-304.
50. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155:601-7.
51. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100:269-77.
52. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339(8791):441-5.
53. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975-82.
54. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-81.
55. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334:682-7.
56. De Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123:1-9.
57. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Hemost 1993; 70:554-61.
58. Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol 1995; 91:736-8.
59. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Th'roux P. New antithrombotics. Chest 1995; 108 Suppl.:471S-85S.
60. McLean J. The thromboplastic action of cephalin. Am J Physiol 1976; 41:250-7.
61. Link KP. The discovery of dicoumarol and its sequels. Circulation 1959; 19:97-107.